Takeda in the news

Takeda presented positive Phase 3 results for its psoriasis drug zasocitinib and announced upcoming oncology pipeline presentations at a medical congress.

Takeda Pharmaceutical's new Phase 3 data for zasocitinib in psoriasis shows strong potential, driving analyst expectations for a significant financial turnaround by 2029.

Takeda entered a global oncology partnership with Innovent Biologics, involving a USD 1.20 billion upfront payment to Innovent, for the development, manufacturing, and commercialization of IBI363 and IBI343.

Takeda's AI-aided psoriasis pill, zasocitinib, showed superior efficacy in a Phase 3 trial and is now under FDA priority review for potential approval.

Corus International received a $6.4 million grant from Takeda to establish a five-year program in Nepal aimed at mitigating climate-related health risks, strengthening early warning systems, infrastructure, and rapid response for over 150,000 people.

Corus International received a $6.4 million grant from Takeda to mitigate climate-related health risks in Nepal.

Takeda Pharmaceutical's new psoriasis drug data suggests it is undervalued, with future growth expected from its pipeline despite recent stock cooling.

Takeda Pharmaceuticals is entering a pivotal three-year period where its global transformation and new product pipeline are expected to deliver significant earnings growth.

Takeda, a biopharmaceutical company, is fundamentally transforming its R&D and overall operations by embedding AI across the organization, driven by strong leadership commitment and significant investments in technology and employee upskilling.

Takeda's stock performance and pipeline, including positive trial data for zasocitinib, are being evaluated against its sales base to determine if its current valuation is justified, with some models suggesting it is undervalued.

Takeda Pharmaceutical's stock is considered undervalued after positive Phase 3 data for its psoriasis drug zasocitinib, alongside strong market performance and a promising pipeline outlook.

Allana Sanborn was appointed Head of Strategy and Operations and Chief of Staff for Global Oncology Product and Pipeline Strategy within Takeda Oncology.

Takeda's zasocitinib showed superior efficacy and was well-tolerated in Phase 3 trials for moderate-to-severe plaque psoriasis compared to a marketed rival, leading to FDA priority review.

Takeda announced positive Phase 3 results for zasocitinib in plaque psoriasis, but its stock appears overvalued with some financial weaknesses despite guru interest.

Keros Therapeutics is set to receive a $20 million milestone payment from Takeda following the start of a Phase 3 trial for elritercept in myelofibrosis.

Keros Therapeutics anticipates a $20 million payment from Takeda after dosing the first patient in a Phase 3 clinical trial for elritercept, a drug for myelofibrosis and anemia.

Keros Therapeutics is set to receive a $20 million milestone payment from partner Takeda after dosing the first patient in a Phase 3 clinical trial for elritercept, a drug targeting blood cell disorders.

Ginkgo Datapoints and Apheris formed a consortium with pharma companies, including Takeda, to build a large antibody developability dataset and AI models for early risk prediction.

Takeda is integrating AI into all phases of drug discovery and development to improve success rates and operational efficiency, while also emphasizing a two-horizon growth strategy and external partnerships.

Takeda's ADHD drug Elvanse had its patent extension upheld in a UK court, despite questions about its inactive precursor and a conflicting German decision.